Curida teams up with leading Nasal Spray Expert, strengthening Development Services
The Oslo Cancer Cluster Member Curida, which is a Contract Development and Manufacturing Organization (CDMO) based in Norway, strengthens its Development Services with a strategic partnership with Dr. René Bommer. Dr. Bommer is known for his competency within Nasal Spray and chairs the annual Nasal Drug Delivery conference. He is also a member of the jury panel at CPHI Pharma Awards. In July 2015, Curida acquired a Takeda manufacturing site with more than 25 years of nasal spray manufacturing experience.
Dr. René Bommer commented, – Curida’s holistic business approach to consider the unity of product content and delivery device in the development and in the further manufacturing process puts them into a leading position in the pharmaceutical industry. I am delighted to cooperate with such well-focused company and to contribute actively to the business success of Curida.
– We are very happy and proud to having Dr. Bommer joining our team. His knowledge and experience within this complex field is impressive. I have already had the fortune to work with him on a project and his blend of technical in-depth knowledge coupled with a commercial mind-set is quite rare and a strong asset, says Morten Steinvåg, Sales Director at Curida.
Curida’s development expertise covers the full service for the development of nasal and inhalation drug products (OINDP). The cGMP compliant laboratory service includes the extensive performance characterisation studies for nasal and inhalation drug products (OINDP) and other dosage forms provided with a delivery device, such as ophthalmic or topical products.
For the development of generic products, Curida is able to perform the regulatory challenging in-vitro bioequivalence studies and is responsible for the relevant CMC documentation for submission to the authorities.
Preservative free, sterile nasal and ophthalmic drug products fitted with multi dose delivery devices become more and more popular. In addition to physical device performance characterisation, Curida develops and validates the microbiological protocols and assesses the microbiological integrity of the product during shelf life and in particular during the in-use period.
Coupled with the manufacturing capabilities, Curida provides a one-stop solution from development to manufacture of drug products combined with a delivery device.
